Bausch Health Cos Free Cash Flow 2010-2024 | BHC

Bausch Health Cos free cash flow from 2010 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
Bausch Health Cos Annual Free Cash Flow
2023 817.00
2022 -946.00
2021 1,826.00
2020 830.00
2019 1,276.00
2018 1,378.00
2017 5,372.00
2016 2,051.00
2015 2,035.00
2014 3,512.00
2013 967.80
2012 641.00
2011 617.96
2010 261.41
2009 381.78
Bausch Health Cos Quarterly Free Cash Flow
2024-09-30 765.00
2024-06-30 431.00
2024-03-31 129.00
2023-12-31 817.00
2023-09-30 525.00
2023-06-30 285.00
2023-03-31 107.00
2022-12-31 -946.00
2022-09-30 -1,355.00
2022-06-30 -38.00
2022-03-31 -109.00
2021-12-31 1,826.00
2021-09-30 1,880.00
2021-06-30 735.00
2021-03-31 381.00
2020-12-31 830.00
2020-09-30 495.00
2020-06-30 341.00
2020-03-31 210.00
2019-12-31 1,276.00
2019-09-30 1,119.00
2019-06-30 676.00
2019-03-31 391.00
2018-12-31 1,378.00
2018-09-30 1,119.00
2018-06-30 591.00
2018-03-31 397.00
2017-12-31 5,372.00
2017-09-30 4,657.00
2017-06-30 1,147.00
2017-03-31 916.00
2016-12-31 2,051.00
2016-09-30 1,525.00
2016-06-30 988.00
2016-03-31 495.00
2015-12-31 2,035.00
2015-09-30 1,498.90
2015-06-30 789.00
2015-03-31 425.30
2014-12-31 3,512.00
2014-09-30 2,747.60
2014-06-30 688.70
2014-03-31 426.20
2013-12-31 967.80
2013-09-30 737.80
2013-06-30 561.00
2013-03-31 249.70
2012-12-31 641.00
2012-09-30 583.84
2012-06-30 463.37
2012-03-31 222.36
2011-12-31 617.96
2011-09-30 443.13
2011-06-30 279.01
2011-03-31 64.83
2010-12-31 261.41
2010-09-30 272.02
2010-06-30 155.71
2010-03-31 49.66
2009-12-31 381.78
2009-09-30 241.03
2009-06-30 147.73
2009-03-31 46.19
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.931B $8.757B
Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.395B 6.36
Dr Reddy's Laboratories (RDY) India $11.853B 22.68
BridgeBio Pharma (BBIO) United States $4.426B 0.00
Amphastar Pharmaceuticals (AMPH) United States $2.186B 13.14
Supernus Pharmaceuticals (SUPN) United States $2.000B 27.23
Taysha Gene Therapies (TSHA) United States $0.506B 35.29
Personalis (PSNL) United States $0.245B 0.00
Assembly Biosciences (ASMB) United States $0.096B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00